Replimune Group (NASDAQ:REPL) CFO Emily Luisa Hill Sells 11,448 Shares

Replimune Group, Inc. (NASDAQ:REPL) CFO Emily Luisa Hill sold 11,448 shares of Replimune Group stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,480.56. Following the sale, the chief financial officer owned 225,108 shares of the company’s stock, valued at $2,919,650.76. The trade was a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Performance

Shares of NASDAQ REPL traded up $1.59 during mid-day trading on Wednesday, hitting $15.24. The stock had a trading volume of 8,269,132 shares, compared to its average volume of 5,046,735. The firm has a market cap of $1.28 billion, a PE ratio of -4.51 and a beta of 0.88. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. The company has a 50 day moving average of $10.34 and a two-hundred day moving average of $7.64. Replimune Group, Inc. has a twelve month low of $1.50 and a twelve month high of $15.68.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Research analysts predict that Replimune Group, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Replimune Group during the 2nd quarter worth about $99,171,000. RTW Investments LP grew its holdings in Replimune Group by 11.6% in the fourth quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock valued at $69,404,000 after purchasing an additional 744,620 shares during the period. State Street Corp grew its holdings in Replimune Group by 26.3% in the fourth quarter. State Street Corp now owns 3,693,107 shares of the company’s stock valued at $35,897,000 after purchasing an additional 768,982 shares during the period. Vanguard Group Inc. increased its position in shares of Replimune Group by 0.3% in the third quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock valued at $14,579,000 after buying an additional 9,707 shares in the last quarter. Finally, Balyasny Asset Management L.P. raised its stake in shares of Replimune Group by 507.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after buying an additional 2,195,448 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on REPL. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $11.00 to $17.00 in a research report on Tuesday, August 4th. Weiss Ratings downgraded Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a report on Wednesday. Finally, Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Replimune Group has an average rating of “Moderate Buy” and an average target price of $11.86.

Key Replimune Group News

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: $150 million offering priced: Replimune priced a $150 million underwritten public offering, providing additional cash to support development of its oncology pipeline and RP1. The financing appears to have reassured investors about the company’s liquidity and ability to fund operations. Replimune Announces Pricing of $150 Million Underwritten Offering
• Neutral Sentiment: Insider transactions were primarily tax-related: CEO Sushil Patel, CFO Emily Hill, CAO Andrew Schwendenman and insider Konstantinos Xynos sold shares totaling approximately $1.01 million. The filings state that the sales covered tax-withholding obligations tied to vested equity awards, while each executive retained a substantial position; therefore, the transactions provide limited evidence of a change in business confidence. SEC insider transaction filing
• Negative Sentiment: Several law firms publicized a securities class action: The lawsuits cover investors who purchased Replimune securities between October 20, 2025, and April 10, 2026. The allegations claim the company misled investors about the efficacy and commercial viability of RP1 and failed to disclose unresolved FDA study-design concerns. CEO Sushil Patel and CFO Emily Hill are named as individual defendants, and the lead-plaintiff deadline is October 5, 2026. The notices increase legal and reputational uncertainty, although the allegations have not been proven. REPL Class Action Reminder Levi and Korsinsky class action notice

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.